Harvard Bioscience Inc
HBIO Nasdaq· Laboratory Analytical Instruments
Last close · Oct 27, 2026
$8.35
KIRA · Stoqly’s AI analyst, in plain words
- Harvard Bioscience Inc had $86.6M of revenue in fiscal 2025, down 8.1% on the year before. Over five years, revenue changed −3.3% a year on average.
- Its operating margin was −56.1%, down 49.5 pts: of every 100 in sales, about −56 is left after running the business.
- Harvard Bioscience Inc lost $56.7M in fiscal 2025.
- Free cash flow was $5.5M in fiscal 2025, 6.3% of revenue.
- Harvard Bioscience Inc owes $27.3M more than it holds in cash.
Market cap
$37.8M
P/E
0.9x
Revenue
$86.6M
Net income
−$56.7M
Free cash flow
$5.5M
Operating margin
−56.1%
Harvard Bioscience Inc in 30 seconds · fiscal 2025
Are sales growing?
−8.1%
No. Sales fell 8.1% last year.
Does it make a profit?
−65.5%
No. It lost money last year.
Does profit turn into cash?
6.3%
Partly. 6.3% of sales ends up as free cash.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
0.9x
One share costs 0.9 times its yearly profit per share.
What Harvard Bioscience Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 13, 2026
- Legal name
- HARVARD BIOSCIENCE INC
- CIK
- 0001123494
Harvard Bioscience Inc · HBIO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $119M | $113M | $112M | $94.1M | $86.6M |
| Revenue growth | 16.5% | −4.7% | −1.0% | −16.1% | −8.1% |
| Gross margin | 56.9% | 53.7% | 58.9% | 58.2% | 57.7% |
| Operating margin | 1.7% | −6.1% | 1.7% | −6.6% | −56.1% |
| Net income | −$0.3M | −$9.5M | −$3.4M | −$12.4M | −$56.7M |
| Net margin | −0.2% | −8.4% | −3.0% | −13.2% | −65.5% |
| Diluted EPS | −$0.01 | −$0.23 | −$0.08 | −$0.28 | −$1.28 |
| Cash | |||||
| Cash from operations | $1.3M | $1.2M | $14.0M | $1.4M | $6.7M |
| Capital expenditure | $1.2M | $1.6M | $1.8M | $2.6M | $1.3M |
| Free cash flow | $0.1M | −$0.4M | $12.2M | −$1.2M | $5.5M |
| FCF margin | 0.1% | −0.4% | 10.9% | −1.3% | 6.3% |
| Share count change | 4.4% | 2.7% | 2.4% | 2.6% | 2.0% |
| Debt and strength | |||||
| Cash and short-term investments | $7.8M | $4.5M | $4.3M | $4.1M | $8.6M |
| Debt incl. finance leases | $48.3M | $46.8M | $37.0M | $37.0M | $35.9M |
| Shareholders' equity | $83.4M | $72.2M | $73.1M | $63.3M | $13.7M |
| Net debt / EBITDA | 10.5x | — | 9.7x | — | — |
| Current ratio | 2.4x | 2.2x | 1.8x | 0.8x | 2.2x |
| Interest coverage | — | — | — | −7.8x | −37.4x |
| Returns and quality | |||||
| Return on capital | 1.3% | −4.8% | 1.4% | −5.1% | −93.6% |
| Return on equity | −0.4% | −12.2% | −4.7% | −18.2% | −147.1% |
| Piotroski F-score | 6 | 3 | 6 | 2 | 4 |
| Altman Z'' | −0.0 | −1.2 | −1.1 | −3.9 | −10.4 |
Insiders bought, 12 months
$0.2M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Harvard Bioscience Inc · HBIO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $8.35 a share, the company is worth $37.8M: 0.9 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001123494). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.